Northwire Canada EditionMonday, July 13, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Organigram Reports Record Fourth Quarter and Fiscal 2025 Results

OGI · Price

Executive Summary

  • Organigram reported record fiscal‑2025 results: gross revenue $403.0 M (+63% YoY) and adjusted EBITDA $21.9 M (+160% YoY).
  • International sales surged to $26.3 M, a 173% increase year‑over‑year, driven by new product launches and recent acquisitions (Motif Labs Ltd. and Collective Project Limited).
  • The company announced an upcoming conference call on December 16, 2025 to discuss the results and provided forward‑looking guidance for fiscal 2026 revenue > $300 M.

Key Details

  • Fiscal 2025 Financial Highlights
  • Gross Revenue: $403.0 M (+63% YoY)
  • Net Revenue: $259.2 M (+62% YoY)
  • Adjusted Gross Margin: $91.0 M (35% of net revenue)
  • Adjusted EBITDA: $21.9 M (+160% YoY)
  • Net Loss: $(24.8 M) (down 46% from prior year)

  • Q4 2025 Financial Highlights

  • Gross Revenue: $123.3 M (+76% YoY)
  • Net Revenue: $80.1 M (+79% YoY)
  • Adjusted EBITDA: $9.8 M (+69% YoY)

  • International Business

  • Record International Sales: $26.3 M, up 173% YoY (vs. $9.7 M in FY 2024).
  • Launched “happly” edibles powered by FAST™ technology in the U.S.

  • Acquisitions & Strategic Initiatives

  • Acquired Motif Labs Ltd. – expanded Ontario footprint, extraction capacity; realized ~$7.1 M of $15 M identified synergies to date.
  • Acquired Collective Project Limited – entry into Canadian and U.S. cannabinoid‑beverage markets.
  • Launched FAST™ platform for ingestible products.

  • Operational Highlights

  • Record harvest achieved via seed‑based cultivation, upgraded lighting, and improved room turns.
  • Identified genetic markers for powdery mildew resistance; breeding program underway.

  • Balance Sheet (as of Sept 30 2025)

  • Cash & short‑term investments: $84.4 M (down 37% YoY).
  • Total assets: $562.2 M, up 37% YoY.
  • Total liabilities: $213.1 M, up 109% YoY.

  • Guidance for Fiscal 2026

  • Expected net revenue > $300 M.
  • Anticipated margin expansion from continued domestic/international demand and operational efficiencies.

  • Conference Call Details

  • Date: December 16, 2025, 8:00 am ET.
  • Registration link: https://registrations.events/direct/Q4I9676638
  • Webcast replay available on Organigram’s investor site within 24 hours and retained for 90 days.

Notable Quotes

  • “Fiscal 2025 was marked by purposeful growth… Our acquisitions broadened our capabilities… We expanded our international presence…” – Peter Amirault, Executive Chair
  • “Looking to Fiscal 2026, we believe we are well‑positioned for strong revenue growth with net revenue expected to exceed $300 million…” – Greg Guyatt, CFO
Read the original news release →

More from ORGANIGRAM GLOBAL INC.